Skip to content
Search

Latest Stories

50 million face masks will not be used in NHS over safety concerns

Government says it won’t be using 50 million face masks it bought during a scramble to secure protective equipment for medics during the coronavirus outbreak because of concerns they might not be safe.

The admission sparked calls from opposition parties for an urgent inquiry into the way contracts for essential supplies were handed out.


The masks were part of a £252 million contract the government signed with investment firm Ayanda Capital in April. Papers filed in a court case reveal that the masks won’t be distributed because they have ear loops rather than head loops and may not fit tightly enough.

The papers, published on Thursday (Aug 6), are part of a lawsuit against the government by campaigning groups the Good Law Project and EveryDoctor. They want the courts to review contracts signed by the government for personal protective equipment, which they say were not properly scrutinized.

The groups estimate the 50 million rejected masks cost about £150 million, though the government has not confirmed the amount and it is unclear whether the full £252 million agreed to in the deal was ever paid.

As the coronavirus outbreak accelerated across the U.K. in March, it became clear that the country lacked enough masks, gloves, gowns and other protective gear for health care workers and nursing home staff. That sparked a race to buy billions of pieces of equipment from suppliers around the world.

Jolyon Maugham, director of the Good Law Project, said the government had signed three contracts worth more than 100 million pounds each “with respectively a pest control company, a confectioner and a family hedge fund.”

“Each of those contracts has revealed real cause for alarm,” he said.

The government said in its response to the lawsuit that the offer to supply the 50 million masks came from Andrew Mills, a businessman who is both an adviser to the government’s Board of Trade and to Ayanda Capital. Mills has denied there was any conflict of interest.

Ayanda Capital chief executive Tim Horlick said the masks met government standards and were not “unusable or unsafe.”

He said National Health Service requirements may have changed in the fast-moving circumstances of the pandemic.

The British government said another 150 million masks of a different type supplied by Ayanda are still being tested.

It said in a statement that “there is a robust process in place to ensure orders are of high quality and meet strict safety standards, with the necessary due diligence undertaken on all government contracts.”

Prime Minister Boris Johnson said he was “very disappointed” that the shipment was unusable. But he said Britain had “achieved a colossal race against time” to obtain supplies of equipment and stockpile it in case of a second wave of coronavirus in the fall and winter.

Keir Starmer, leader of the main opposition Labour Party, called for an urgent investigation into the way personal protective equipment was acquired.

“It’s just not good enough to people who need that protective equipment that we find ourselves in this position,” he said. (AP)

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less